Results 221 to 230 of about 86,846 (266)

Determinants of Response to Immune Checkpoint Blockade in Pleural Mesothelioma: Molecular, Immunological, and Clinical Perspectives. [PDF]

Cancers (Basel)
Delsignore M, Cassinari G, Revello S, Cerbone L, Grosso F, Arsura M, Porta C.   +6 more
europepmc   +1 more source

Ferroptotic tumor cells reprogram tumor-associated macrophage antigen presentation to enhance the efficacy of immune checkpoint blockade. [PDF]

Cell Rep Med
Sun JL, Chu YC, Wang F, Yu DD, Liu JR, Xu RC, Liu HH, Qi ZR, Shi X, Yu XN, Yao YK, Liu TT, Weng SQ, Dong L, Shen XZ, Hu SB, Sun T, Zhu JM.   +17 more
europepmc   +1 more source

<i>PPP2R1A</i> Mutation: A Critical Amplifier for Immune Checkpoint Blockade Therapy Efficacy. [PDF]

MedComm (2020)
Gu Y, Zhang Z, Zhou F.
europepmc   +1 more source

Inhibition of glutamine metabolism blocks tumor growth and sensitizes ccRCC to immune checkpoint blockade. [PDF]

J Transl Med
Ma G, Jia H, Tian X, Wang G, Zhang X, Mi Z, Jia Y, Wang L, Liang Z, Li D, Mao X, Liang Y, Niu H.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Immune Checkpoint Blockade

Hematology/Oncology Clinics of North America, 2014
Since the development and approval of Ipilimumab, the first immune checkpoint inhibitor licensed for the treatment of metastatic melanoma, clinicians have gained a better understanding of the mode of action, management of toxicities, and assessment of response to this class of drugs.
Jarushka, Naidoo, David B, Page, Jedd D, Wolchok   +2 more
openaire   +2 more sources

The future of microfluidics in immune checkpoint blockade

Cancer Gene Therapy, 2020
Recent advances in microfluidic techniques have enabled researchers to study sensitivities to immune checkpoint therapy, to determine patients' response to particular antibody treatment. Utilization of this technology is helpful in antibody discovery and in the design of personalized medicine.
Jonathan Briones, Wilfred Espulgar, Shohei Koyama, Hyota Takamatsu, Eiichi Tamiya, Masato Saito   +5 more
openaire   +2 more sources

Immune Checkpoint Blockade in Malignant Mesothelioma

Seminars in Oncology, 2015
Malignant mesothelioma (MM) is a highly aggressive malignancy with a very dismal prognosis. Current treatment for unresectable MM is largely unsatisfactory; therefore, new therapeutic approaches are eagerly awaited. A better understanding of the complex mechanisms of immune escape operated by neoplastic cells and the ability to unleash an efficient ...
Calabro' L, Maio M.
openaire   +3 more sources

Combined Immune Checkpoint Blockade

Seminars in Oncology, 2015
There are very few tumor types for which chemotherapy regimens are regularly curative; notable exceptions include testicular cancer and Hodgkin's lymphoma. In both cases combination chemotherapy approaches are required. Thus, it would seem only logical that combination immunotherapy approaches will be required to induce long-term remissions in the ...
openaire   +2 more sources

Combining chemotherapy and immune checkpoint blockade

Current Opinion in Urology, 2016
Immune checkpoint blockade results in durable responses in a subset of patients with advanced urologic tumors. However, the majority of patients do not respond to single agent therapy raising the hypothesis that combination regimens may extend the benefits of immune checkpoint blockade to an even broader patient population.
Ana, Collazo-Lorduy, Matthew D, Galsky
openaire   +2 more sources

A Review of Immune Checkpoint Blockade for the General Surgeon

Journal of Surgical Research, 2023
The immune system is a complex and interconnected system that has evolved to protect its host from foreign pathogens. CD8+ T cells are a type of immune cell that can be directly lethal to tumor cells. However, their tumor killing capabilities can be inhibited by checkpoint molecules.
Xavier L. Baldwin, Philip M. Spanheimer, Stephanie Downs-Canner   +2 more
openaire   +2 more sources